BioNexus Gene Lab Corp. (NASDAQ:BGLC) Sees Large Decline in Short Interest

BioNexus Gene Lab Corp. (NASDAQ:BGLC – Get Free Report) was the recipient of a significant decline in short interest during the month of October. As of October 30th, there was short interest totaling 3,180 shares, a decline of 64.9% from the October 15th total of 9,051 shares. Based on an average daily volume of 3,299 shares, the short-interest ratio is currently 1.0 days. Currently, 0.1% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of BioNexus Gene Lab from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, September 18th. One investment analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock currently has an average rating of “Sell”.

Read Our Latest Analysis on BGLC

BioNexus Gene Lab Stock Performance

Shares of BGLC opened at $0.82 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.08 and a quick ratio of 5.28. BioNexus Gene Lab has a one year low of $0.81 and a one year high of $4.97. The firm has a market capitalization of $2.41 million, a P/E ratio of -0.65 and a beta of 4.28. The business has a fifty day moving average of $1.22 and a 200 day moving average of $1.86.

BioNexus Gene Lab (NASDAQ:BGLC – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.12) EPS for the quarter. BioNexus Gene Lab had a negative net margin of 82.38% and a negative return on equity of 32.92%. The firm had revenue of $0.08 million for the quarter.

BioNexus Gene Lab Company Profile

(Get Free Report)

BioNexus Gene Lab Corp. (NASDAQ: BGLC) is a biotechnology and molecular diagnostics company focused on using genetic and genomic information to support disease screening, risk assessment and personalized healthcare. The company develops and commercializes diagnostic products and laboratory services based on the analysis of biological samples, including blood and other specimens. Its offerings are intended to help identify potential health risks and support the early detection and management of conditions such as cancer and other diseases.

See Also

Receive News & Ratings for BioNexus Gene Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNexus Gene Lab and related companies with MarketBeat.com's FREE daily email newsletter.